Nrx pharmaceuticals announces submission of an investigational new drug (ind) application for nrx-101 in the treatment of chronic pain

Ind builds on previously-published, preliminary evidence of efficacy filing is supported by robust manufacturing, pre-clinical and clinical data already reviewed by fda for nrx-101 associated with treatment of bipolar depression radnor, pa. , aug. 30, 2023 /prnewswire/ - nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", the "company"), a clinical-stage biopharmaceutical company, today announced submission an investigational new drug (ind) application to the u.s. food and drug administration (fda) for the use of nrx-101 to treat chronic pain.
NRXP Ratings Summary
NRXP Quant Ranking